3D Medicines Bleeds Red Ink As It Struggles to Swim in ‘Red Ocean’
The loss-making innovative oncology drug company with just one approved product on the market is making a third tilt for a listing on the Hong Kong Stock Exchange Key Takeaways:…
RELATED ARTICLES
-
Vanke bleeds red ink but detects signs of upturn
2202.HK 000002.SHE -
Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
688062.SHG
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
- Youlife chases SPAC listing after death of Hong Kong IPO
- Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
